Envudeucitinib for Active Systemic Lupus Erythematosus

Envudeucitinib for Active Systemic Lupus Erythematosus
45%34%23%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 38.0%May 28 • YES 29.9%
Alumis Inc ($ALMS)
No stock close$22.52$21.74$20.96May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • ALMS $21.15May 19 • ALMS $21.53May 20 • ALMS $22.04May 21 • ALMS $22.17May 22 • ALMS $22.02May 26 • ALMS $22.33May 27 • ALMS $21.33May 28 • ALMS $21.40

Will this trial show a positive result on proportion of patients with BICLA lupus disease-activity response at Week 48?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Systemic lupus erythematosus is a long-term autoimmune disease that can inflame joints, skin, kidneys, brain, heart, lungs, and blood. A response score matters because it shows whether inflammation is calmer and daily symptoms are less likely to worsen.

1U.S. Prevalence: 72.8 per 100,0002Sex Disparity: About 9 in 10 are women3Kidney Burden: Up to 5 in 10 adults